BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Atherosclerotic Cardiovascular Disease readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Atherosclerotic Cardi
 ovascular Disease\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06496243-401@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Obicetrapib: Phase 2 readout est. (NCT06496243)
DESCRIPTION:Obicetrapib\, phase 2\, Atherosclerotic Cardiovascular Disease.
 \nStudy: Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Level
 s\nEstimated primary completion: November 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/obicetrapib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06496243
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06496243-1032@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Repatha (Evolocumab): Phase 2 readout est. (NCT06496243)
DESCRIPTION:Repatha (Evolocumab)\, phase 2\, Atherosclerotic Cardiovascular
  Disease.\nStudy: Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp
 (a) Levels\nEstimated primary completion: November 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/evolocumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06496243
URL:https://assetmemo.bio/drug/evolocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05202509-401@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Obicetrapib: Phase 3 readout est. (NCT05202509)
DESCRIPTION:Obicetrapib\, phase 3\, Atherosclerotic Cardiovascular Disease.
 \nStudy: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapi
 b in Patients With Cardiovascular Disease\nEstimated primary completion: N
 ovember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obicetr
 apib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05202509
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729475-1077@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:SAL0137: Phase 2 readout est. (NCT07729475)
DESCRIPTION:SAL0137\, phase 2\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Phase II\, Randomized\, Double-Blind\, Placebo-Controlled Study of 
 Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovas
 cular Events\nEstimated primary completion: 12 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sal0137#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07729475
URL:https://assetmemo.bio/drug/sal0137#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07477704-1033@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20261229
DTEND;VALUE=DATE:20261230
SUMMARY:Praluent (Alirocumab): Phase 2 readout est. (NCT07477704)
DESCRIPTION:Praluent (Alirocumab)\, phase 2\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: A Study to See How Safe and Effective Alirocumab is Whe
 n Given Weekly to Adult Participants Who Have Hypercholesterolemia\nEstima
 ted primary completion: 29 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/alirocumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07477704
URL:https://assetmemo.bio/drug/alirocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577519-8692@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sumecigrel: Phase 3 readout est. (NCT06577519)
DESCRIPTION:Sumecigrel\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: Efficacy and Safety Study of Vicagrel in Patients With Acute Coron
 ary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)\nEs
 timated primary completion: 30 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sumecigrel#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06577519
URL:https://assetmemo.bio/drug/sumecigrel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000136-1050@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270104
DTEND;VALUE=DATE:20270105
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07000136)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Pa
 tients With HeFH\nEstimated primary completion: 4 January 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/laroprovstat#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07000136
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000123-1050@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07000123)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Pa
 tients With Clinical ASCVD or at Risk for a First ASCVD Event\nEstimated p
 rimary completion: 11 January 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/laroprovstat#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07000123
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102628-1034@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT07102628)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Evaluation of Efficacy and Safety of Early in Hospital In
 itiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
 \nEstimated primary completion: 16 January 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07102628
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767513-1081@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:HRS-5346: Phase 2 readout est. (NCT07767513)
DESCRIPTION:HRS-5346\, phase 2\, Atherosclerotic Cardiovascular Disease.\nS
 tudy: Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a
 ) and High Risk of Cardiovascular Events\nEstimated primary completion: Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-5346
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 67513
URL:https://assetmemo.bio/drug/hrs-5346#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06927739-1122@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270208
DTEND;VALUE=DATE:20270209
SUMMARY:Orticumab: Phase 2 readout est. (NCT06927739)
DESCRIPTION:Orticumab\, phase 2\, Atherosclerotic Cardiovascular Disease.\n
 Study: Focused Orticumab Research for Treating Inflammation in Coronary Ar
 teries\nEstimated primary completion: 8 February 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/orticumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06927739
URL:https://assetmemo.bio/drug/orticumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06834932-1050@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:Laroprovstat: Phase 2/3 readout est. (NCT06834932)
DESCRIPTION:Laroprovstat\, phase 2/3\, Atherosclerotic Cardiovascular Disea
 se.\nStudy: A Study to Evaluate the Efficacy\, Safety\, and Pharmacokineti
 cs of AZD0780 in Participants With Dyslipidaemia\nEstimated primary comple
 tion: 22 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/laroprovstat#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06834932
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06774040-7938@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Etribnabdione: Phase 2 readout est. (NCT06774040)
DESCRIPTION:Etribnabdione\, phase 2\, Atherosclerotic Cardiovascular Diseas
 e.\nStudy: Evaluation of Safety\, Tolerability and Preliminary Efficacy of
  Etrinabdione in Patients With Peripheral Arterial Disease\nEstimated prim
 ary completion: March 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/etribnabdione#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06774040
URL:https://assetmemo.bio/drug/etribnabdione#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07269210-1093@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Solbinsiran: Phase 2 readout est. (NCT07269210)
DESCRIPTION:Solbinsiran\, phase 2\, Atherosclerotic Cardiovascular Disease.
 \nStudy: A Study of Solbinsiran (LY3561774) in Participants With Severe Hy
 pertriglyceridemia\nEstimated primary completion: March 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/solbinsiran#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07269210
URL:https://assetmemo.bio/drug/solbinsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185776-1207@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:HRS-5632: Phase 2 readout est. (NCT07185776)
DESCRIPTION:HRS-5632\, phase 2\, Atherosclerotic Cardiovascular Disease.\nS
 tudy: A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(
 a) at High Risk for Cardiovascular Events\nEstimated primary completion: A
 pril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-5632#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07185
 776
URL:https://assetmemo.bio/drug/hrs-5632#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06217120-1199@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Lodoco (Colchicine (cardiovascular)): Phase 2 readout est. (NCT0621
 7120)
DESCRIPTION:Lodoco (Colchicine (cardiovascular))\, phase 2\, Atheroscleroti
 c Cardiovascular Disease.\nStudy: Reversing Microvascular Dysfunction in H
 eart Failure With Preserved Ejection Fraction\nEstimated primary completio
 n: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/colchi
 cine-cardiovascular#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06217120
URL:https://assetmemo.bio/drug/colchicine-cardiovascular#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235046-1076@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270426
DTEND;VALUE=DATE:20270427
SUMMARY:BW-20829: Phase 2 readout est. (NCT07235046)
DESCRIPTION:BW-20829\, phase 2\, Atherosclerotic Cardiovascular Disease.\nS
 tudy: A Study of DII235 in Adults With Elevated Lipoprotein(a)\nEstimated 
 primary completion: 26 April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bw-20829#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07235046
URL:https://assetmemo.bio/drug/bw-20829#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07695597-1097@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:SYH2070: Phase 2 readout est. (NCT07695597)
DESCRIPTION:SYH2070\, phase 2\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemi
 a\nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/syh2070#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07695597
URL:https://assetmemo.bio/drug/syh2070#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05030428-1034@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT05030428)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study of Inclisiran to Prevent Cardiovascular (CV) Events
  in Participants With Established Cardiovascular Disease\nEstimated primar
 y completion: 10 May 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/inclisiran#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05030428
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619118-5401@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07619118)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholeste
 rolaemia\nEstimated primary completion: 28 May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07619118
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619118-8630@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:laroprovstat/rosuvastatin: Phase 3 readout est. (NCT07619118)
DESCRIPTION:laroprovstat/rosuvastatin\, phase 3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: A Phase III Study to Assess the Effect of FDC Larop
 rovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With 
 Hypercholesterolaemia\nEstimated primary completion: 28 May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/laroprovstat-rosuvastatin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0761911
 8
URL:https://assetmemo.bio/drug/laroprovstat-rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07898709-306@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0789870
 9)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Atherosclerotic C
 ardiovascular Disease.\nStudy: Evaluating SGLT2 Inhibitors for the Reducti
 on of No-Reflow Phenomenon in Patients Undergoing PCI\nEstimated primary c
 ompletion: June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07898709
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07898709-308@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07898709)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: Evaluating SGLT2 Inhibitors for the Reduction of No
 -Reflow Phenomenon in Patients Undergoing PCI\nEstimated primary completio
 n: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empagli
 flozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07898709
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391722-1057@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:DNV001: Phase 2 readout est. (NCT07391722)
DESCRIPTION:DNV001\, phase 2\, Atherosclerotic Cardiovascular Disease.\nStu
 dy: DNV001 Injection in Patients With Hypercholesterolemia\nEstimated prim
 ary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/dnv001#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07391722
URL:https://assetmemo.bio/drug/dnv001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352800-1263@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:APAC: Phase 2 readout est. (NCT07352800)
DESCRIPTION:APAC\, phase 2\, Atherosclerotic Cardiovascular Disease.\nStudy
 : Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral
  Arterial Occlusive Disease and Chronic Limb-threatening Ischemia\nEstimat
 ed primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/apac#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07352800
URL:https://assetmemo.bio/drug/apac#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623915-6854@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nexletol (Bempedoic acid): Phase 3 readout est. (NCT07623915)
DESCRIPTION:Nexletol (Bempedoic acid)\, phase 3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: A Clinical Study to Evaluate the Efficacy and Safet
 y of Bempedoic Acid\nEstimated primary completion: 30 June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bempedoic-acid#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07623915
URL:https://assetmemo.bio/drug/bempedoic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619131-1050@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07619131)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin and Placebo on LDL-C in 
 LLT-naïve Patients.\nEstimated primary completion: 30 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/laroprovstat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07619131
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619131-5401@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07619131)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin and Placebo on LDL-C in 
 LLT-naïve Patients.\nEstimated primary completion: 30 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07619131
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619131-8630@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:laroprovstat/rosuvastatin: Phase 3 readout est. (NCT07619131)
DESCRIPTION:laroprovstat/rosuvastatin\, phase 3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: A Phase III Study to Assess the Effect of FDC Larop
 rovstat/Rosuvastatin Compared With Laroprovstat\, Rosuvastatin and Placebo
  on LDL-C in LLT-naïve Patients.\nEstimated primary completion: 30 July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/laroprovstat-ros
 uvastatin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07619131
URL:https://assetmemo.bio/drug/laroprovstat-rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07521007-1257@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:YN001: Phase 2 readout est. (NCT07521007)
DESCRIPTION:YN001\, phase 2\, Atherosclerotic Cardiovascular Disease.\nStud
 y: A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclero
 sis\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/yn001#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07521007
URL:https://assetmemo.bio/drug/yn001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07440381-6854@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nexletol (Bempedoic acid): Phase 3 readout est. (NCT07440381)
DESCRIPTION:Nexletol (Bempedoic acid)\, phase 3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: triPle Oral thERapy With Bempedoic Acid vs uSual Ca
 re in Early Lipid Management of Patients With acUte coronAry synDromE\nEst
 imated primary completion: August 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/bempedoic-acid#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07440381
URL:https://assetmemo.bio/drug/bempedoic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05918861-1099@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Dalcetrapib: Phase 3 readout est. (NCT05918861)
DESCRIPTION:Dalcetrapib\, phase 3\, Atherosclerotic Cardiovascular Disease.
 \nStudy: Effect of Dalcetrapib on CV Risk in a Genetically Defined Populat
 ion With a Recent ACS\nEstimated primary completion: August 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/dalcetrapib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05918861
URL:https://assetmemo.bio/drug/dalcetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05476991-6104@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT05476991)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: Evaluation of Low Dose Colchicine and Ticagrelor in Pre
 vention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis\
 nEstimated primary completion: 1 September 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05476991
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591298-1097@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270916
DTEND;VALUE=DATE:20270917
SUMMARY:SYH2070: Phase 2 readout est. (NCT07591298)
DESCRIPTION:SYH2070\, phase 2\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH207
 0 Injection in Participants With Homozygous Familial Hypercholesterolemia\
 nEstimated primary completion: 16 September 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/syh2070#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07591298
URL:https://assetmemo.bio/drug/syh2070#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07749014-308@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07749014)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: Timing of Empagliflozin in Primary PCI: Pre-Reperfu
 sion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients\
 nEstimated primary completion: 30 September 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07749014
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444086-1055@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20271007
DTEND;VALUE=DATE:20271008
SUMMARY:QLC7401: Phase 3 readout est. (NCT07444086)
DESCRIPTION:QLC7401\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dys
 lipidemia\nEstimated primary completion: 7 October 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/qlc7401#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07444086
URL:https://assetmemo.bio/drug/qlc7401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930507-1050@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07930507)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin\, and Placebo on LDL-C i
 n LLT-naïve Patients\nEstimated primary completion: 11 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/laroprovstat#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07930507
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930507-5401@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07930507)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuv
 astatin Compared With Laroprovstat\, Rosuvastatin\, and Placebo on LDL-C i
 n LLT-naïve Patients\nEstimated primary completion: 11 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07930507
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930507-8630@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:laroprovstat/rosuvastatin: Phase 3 readout est. (NCT07930507)
DESCRIPTION:laroprovstat/rosuvastatin\, phase 3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: A Phase III Study to Assess the Effect of FDC Larop
 rovstat/Rosuvastatin Compared With Laroprovstat\, Rosuvastatin\, and Place
 bo on LDL-C in LLT-naïve Patients\nEstimated primary completion: 11 Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/laroprovstat
 -rosuvastatin#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07930507
URL:https://assetmemo.bio/drug/laroprovstat-rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614984-1081@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:HRS-5346: Phase 2 readout est. (NCT07614984)
DESCRIPTION:HRS-5346\, phase 2\, Atherosclerotic Cardiovascular Disease.\nS
 tudy: A Clinical Trial of MK-7262 and Enlicitide in Participants With High
  Lipoprotein(a) (MK-7262-004)\nEstimated primary completion: 12 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-5346#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07614984
URL:https://assetmemo.bio/drug/hrs-5346#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799129-1092@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:EDP167: Phase 2 readout est. (NCT07799129)
DESCRIPTION:EDP167\, phase 2\, Atherosclerotic Cardiovascular Disease.\nStu
 dy: Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP16
 7 in Adults With Mixed Dyslipidemia\nEstimated primary completion: Novembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/edp167#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07799129
URL:https://assetmemo.bio/drug/edp167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07821944-1048@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Lipfendra (Enlicitide): Phase 3 readout est. (NCT07821944)
DESCRIPTION:Lipfendra (Enlicitide)\, phase 3\, Atherosclerotic Cardiovascul
 ar Disease.\nStudy: A Clinical Study of Enlicitide (MK-0616) in Adults Wit
 h Hyperlipidemia in India (MK-0616-038)\nEstimated primary completion: 26 
 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enlici
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07821944
URL:https://assetmemo.bio/drug/enlicitide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06488105-5401@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rosuvastatin: Phase 2 readout est. (NCT06488105)
DESCRIPTION:Rosuvastatin\, phase 2\, Atherosclerotic Cardiovascular Disease
 .\nStudy: Emergency Medicine Cardiovascular Risk Assessment for Lipid Diso
 rders Trial\nEstimated primary completion: 30 November 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06488105
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318155-1143@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SRSD107: Phase 2 readout est. (NCT07318155)
DESCRIPTION:SRSD107\, phase 2\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study of SRSD107 in Participants With Chronic Coronary and/or Perip
 heral Arterial Disease\nEstimated primary completion: December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/srsd107#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07318155
URL:https://assetmemo.bio/drug/srsd107#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441317-1055@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QLC7401: Phase 3 readout est. (NCT07441317)
DESCRIPTION:QLC7401\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyp
 erlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)\nEst
 imated primary completion: December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/qlc7401#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07441317
URL:https://assetmemo.bio/drug/qlc7401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421284-1056@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SYH2053: Phase 3 readout est. (NCT07421284)
DESCRIPTION:SYH2053\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study to Evaluate the Safety\, Efficacy of SYH2053 in Chinese Parti
 cipants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on
  a Background of Lipid-lowering Therapy\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/syh205
 3#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 421284
URL:https://assetmemo.bio/drug/syh2053#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421297-1056@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SYH2053: Phase 3 readout est. (NCT07421297)
DESCRIPTION:SYH2053\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study to Evaluate the Safety\, Efficacy of SYH2053 as Monotherapy i
 n Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyp
 erlipidemia\nEstimated primary completion: 31 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/syh2053#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07421297
URL:https://assetmemo.bio/drug/syh2053#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07303777-1128@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:ABP-745: Phase 2 readout est. (NCT07303777)
DESCRIPTION:ABP-745\, phase 2\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: Efficacy\, Safety\, and PopPK Profile of ABP-745 in Patients With Ath
 erosclerosis\nEstimated primary completion: January 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/abp-745#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07303777
URL:https://assetmemo.bio/drug/abp-745#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07448038-1127@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Selnoflast: Phase 2 readout est. (NCT07448038)
DESCRIPTION:Selnoflast\, phase 2\, Atherosclerotic Cardiovascular Disease.\
 nStudy: A Study to Evaluate the Efficacy\, Safety\, Pharmacodynamics (PD)\
 , and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammatio
 n in Participants With Atherosclerosis at Risk for Major Adverse Cardiac E
 vents\nEstimated primary completion: 31 January 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/selnoflast#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07448038
URL:https://assetmemo.bio/drug/selnoflast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07803822-1034@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Leqvio (Inclisiran): Phase 2 readout est. (NCT07803822)
DESCRIPTION:Leqvio (Inclisiran)\, phase 2\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Phase 2 Clinical Study of MWX203 Injection Alone or in Co
 mbination With Inclisiran Sodium Injection in Patients With Mixed Dyslipid
 emia\nEstimated primary completion: February 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07803822
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813911-1034@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280203
DTEND;VALUE=DATE:20280204
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06813911)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Backgrou
 nd Inclisiran in Participants With Elevated Lp(a) and Established ASCVD\nE
 stimated primary completion: 3 February 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06813911
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813911-1038@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280203
DTEND;VALUE=DATE:20280204
SUMMARY:Pelacarsen: Phase 3 readout est. (NCT06813911)
DESCRIPTION:Pelacarsen\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclis
 iran in Participants With Elevated Lp(a) and Established ASCVD\nEstimated 
 primary completion: 3 February 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pelacarsen#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06813911
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07465263-1056@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:SYH2053: Phase 3 readout est. (NCT07465263)
DESCRIPTION:SYH2053\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study to Evaluate the SYH2053 Injection in Patients With Heterozygo
 us Familial Hypercholesterolemia (HeFH)\nEstimated primary completion: 28 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/syh205
 3#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 465263
URL:https://assetmemo.bio/drug/syh2053#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05488431-6854@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Nexletol (Bempedoic acid): Phase 2 readout est. (NCT05488431)
DESCRIPTION:Nexletol (Bempedoic acid)\, phase 2\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: Cholesterol and Inflammation Lowering Via Bempedoic
  Acid\, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)\nEstimate
 d primary completion: 1 March 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bempedoic-acid#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05488431
URL:https://assetmemo.bio/drug/bempedoic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06597006-1034@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06597006)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study to Evaluate Safety\, Tolerability and Efficacy of I
 nclisiran in Children With Homozygous Familial Hypercholesterolemia\nEstim
 ated primary completion: 21 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06597006
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06597019-1034@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06597019)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study to Evaluate Efficacy and Safety of Inclisiran in Ch
 ildren With Heterozygous Familial Hypercholesterolemia\nEstimated primary 
 completion: 21 March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/inclisiran#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06597019
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07640217-1078@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:SYH2068: Phase 2 readout est. (NCT07640217)
DESCRIPTION:SYH2068\, phase 2\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Phase II Clinical Study of SYH2068 Injection in Adults With Elevate
 d Lipoprotein(a)\nEstimated primary completion: 30 March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/syh2068#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07640217
URL:https://assetmemo.bio/drug/syh2068#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05581303-1039@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olpasiran: Phase 3 readout est. (NCT05581303)
DESCRIPTION:Olpasiran\, phase 3\, Atherosclerotic Cardiovascular Disease.\n
 Study: Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduct
 ion (OCEAN(a)) - Outcomes Trial\nEstimated primary completion: 31 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/olpasiran#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05581303
URL:https://assetmemo.bio/drug/olpasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07450378-1055@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:QLC7401: Phase 3 readout est. (NCT07450378)
DESCRIPTION:QLC7401\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: QLC7401 in Participants With Heterozygous Familial Hypercholesterolem
 ia (HeFH)\nEstimated primary completion: April 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/qlc7401#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07450378
URL:https://assetmemo.bio/drug/qlc7401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07582835-6104@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Brilinta (Ticagrelor): Phase 3 readout est. (NCT07582835)
DESCRIPTION:Brilinta (Ticagrelor)\, phase 3\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: Study of the Long-term Effects of P2Y12 Inhibitor Monot
 herapy and Coagulation Markers After Percutaneous Coronary Angioplasty.\nE
 stimated primary completion: April 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ticagrelor#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07582835
URL:https://assetmemo.bio/drug/ticagrelor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223593-117@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07223593)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Atherosclerotic Cardiovascu
 lar Disease.\nStudy: Efficacy and Safety of Orforglipron in Participants W
 ith Peripheral Artery Disease\nEstimated primary completion: June 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07223593
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474649-5401@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07474649)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Pat
 ients Without Cardiovascular Events\nEstimated primary completion: 1 June 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074746
 49
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07293260-1039@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Olpasiran: Phase 3 readout est. (NCT07293260)
DESCRIPTION:Olpasiran\, phase 3\, Atherosclerotic Cardiovascular Disease.\n
 Study: Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduct
 ion - Coronary Computed Tomography Angiography Trial\nEstimated primary co
 mpletion: 15 June 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/olpasiran#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07293260
URL:https://assetmemo.bio/drug/olpasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037433-143@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT070374
 33)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcom
 es in Participants With Atherosclerotic Cardiovascular Disease and Overwei
 ght or Obesity\nEstimated primary completion: 30 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07037433
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102511-1049@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Lerochol (Lerodalcibep): Phase 3 readout est. (NCT07102511)
DESCRIPTION:Lerochol (Lerodalcibep)\, phase 3\, Atherosclerotic Cardiovascu
 lar Disease.\nStudy: Study to Evaluate the Efficacy and Safety of Lerodalc
 ibep in Children 6 to 17 Years\, With Heterozygous FH\nEstimated primary c
 ompletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/lerodalcibep#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07102511
URL:https://assetmemo.bio/drug/lerodalcibep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839936-1073@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:VERVE-102: Phase 2 readout est. (NCT07839936)
DESCRIPTION:VERVE-102\, phase 2\, Atherosclerotic Cardiovascular Disease.\n
 Study: A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for
  Cardiovascular Disease\nEstimated primary completion: August 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/verve-102#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07839936
URL:https://assetmemo.bio/drug/verve-102#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07736313-5401@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07736313)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors With St
 atin for ACS Patients\nEstimated primary completion: 1 September 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07736313
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276282-606@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Ziltivekimab: Phase 3 readout est. (NCT07276282)
DESCRIPTION:Ziltivekimab\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Pa
 tients With Acute Myocardial Infarction\nEstimated primary completion: 1 S
 eptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ziltiv
 ekimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07276282
URL:https://assetmemo.bio/drug/ziltivekimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492291-1048@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Lipfendra (Enlicitide): Phase 3 readout est. (NCT06492291)
DESCRIPTION:Lipfendra (Enlicitide)\, phase 3\, Atherosclerotic Cardiovascul
 ar Disease.\nStudy: Open-label Extension Study of Enlicitide Decanoate (MK
 -0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia
  (MK-0616-019) CORALreef Extension\nEstimated primary completion: 13 Octob
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/enlicitide#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06492
 291
URL:https://assetmemo.bio/drug/enlicitide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07741890-306@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0774189
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Atherosclerotic C
 ardiovascular Disease.\nStudy: aDAPt-ANOCA: Dapagliflozin for the Treatmen
 t of Angina With Non-Obstructive Coronary Artery Disease (ANOCA)\nEstimate
 d primary completion: 1 December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07741890
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06383390-118@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:retatrutide: Phase 3 readout est. (NCT06383390)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: The Effect of Retatrut
 ide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults L
 iving With Obesity (TRIUMPH-Outcomes)\nEstimated primary completion: Febru
 ary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retatrutide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063
 83390
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06292013-1040@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Lepodisiran: Phase 3 readout est. (NCT06292013)
DESCRIPTION:Lepodisiran\, phase 3\, Atherosclerotic Cardiovascular Disease.
 \nStudy: A Study to Investigate the Effect of Lepodisiran on the Reduction
  of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotei
 n(a) - ACCLAIM-Lp(a)\nEstimated primary completion: March 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lepodisiran#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06292013
URL:https://assetmemo.bio/drug/lepodisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05739383-1034@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20290416
DTEND;VALUE=DATE:20290417
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT05739383)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: A Study of Inclisiran to Prevent Cardiovascular Events in
  High-risk Primary Prevention Patients.\nEstimated primary completion: 16 
 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inclisira
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 739383
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654231-1199@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Lodoco (Colchicine (cardiovascular)): Phase 2 readout est. (NCT0765
 4231)
DESCRIPTION:Lodoco (Colchicine (cardiovascular))\, phase 2\, Atheroscleroti
 c Cardiovascular Disease.\nStudy: REducing Systemic Inflammation With LOw-
 dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney 
 Disease: A Pilot Randomized Open-Label Trial\nEstimated primary completion
 : 1 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/colchic
 ine-cardiovascular#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07654231
URL:https://assetmemo.bio/drug/colchicine-cardiovascular#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07307989-6695@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Zetia (Ezetimibe): Phase 2 readout est. (NCT07307989)
DESCRIPTION:Zetia (Ezetimibe)\, phase 2\, Atherosclerotic Cardiovascular Di
 sease.\nStudy: Early Statin-Ezetimibe Combination vs. Statin Monotherapy i
 n Stroke With Atherosclerosis\nEstimated primary completion: 31 July 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ezetimibe#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07307989
URL:https://assetmemo.bio/drug/ezetimibe#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07000357-1050@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20291026
DTEND;VALUE=DATE:20291027
SUMMARY:Laroprovstat: Phase 3 readout est. (NCT07000357)
DESCRIPTION:Laroprovstat\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: A Phase III Study of AZD0780 on Major Adverse CV Events in Patie
 nts With a History of ASCVD Events or at High Risk for a First Event\nEsti
 mated primary completion: 26 October 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/laroprovstat#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07000357
URL:https://assetmemo.bio/drug/laroprovstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008756-1048@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20291129
DTEND;VALUE=DATE:20291130
SUMMARY:Lipfendra (Enlicitide): Phase 3 readout est. (NCT06008756)
DESCRIPTION:Lipfendra (Enlicitide)\, phase 3\, Atherosclerotic Cardiovascul
 ar Disease.\nStudy: Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Ca
 rdiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes\nEstimated pr
 imary completion: 29 November 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/enlicitide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06008756
URL:https://assetmemo.bio/drug/enlicitide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07613294-1040@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lepodisiran: Phase 3 readout est. (NCT07613294)
DESCRIPTION:Lepodisiran\, phase 3\, Atherosclerotic Cardiovascular Disease.
 \nStudy: A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arter
 ies of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High
  Risk\nEstimated primary completion: December 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lepodisiran#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07613294
URL:https://assetmemo.bio/drug/lepodisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07517263-1038@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20300109
DTEND;VALUE=DATE:20300110
SUMMARY:Pelacarsen: Phase 3 readout est. (NCT07517263)
DESCRIPTION:Pelacarsen\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: An Open Label Extension (OLE) Study (Following Completion of CTQJ2
 30A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ
 230)\nEstimated primary completion: 9 January 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pelacarsen#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07517263
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05646381-1038@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20300312
DTEND;VALUE=DATE:20300313
SUMMARY:Pelacarsen: Phase 2 readout est. (NCT05646381)
DESCRIPTION:Pelacarsen\, phase 2\, Atherosclerotic Cardiovascular Disease.\
 nStudy: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowerin
 g With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Ste
 nosis\nEstimated primary completion: 12 March 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pelacarsen#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05646381
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282041-127@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Trulicity (dulaglutide): Phase 2/3 readout est. (NCT07282041)
DESCRIPTION:Trulicity (dulaglutide)\, phase 2/3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: Role of GLP1 RA Dulaglutide on Severe Intracranial 
 Atherosclerosis\nEstimated primary completion: 1 December 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/dulaglutide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07282041
URL:https://assetmemo.bio/drug/dulaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06875973-1038@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20301208
DTEND;VALUE=DATE:20301209
SUMMARY:Pelacarsen: Phase 3 readout est. (NCT06875973)
DESCRIPTION:Pelacarsen\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: Pelacarsen Roll-over Extension Program\nEstimated primary completi
 on: 8 December 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pelacarsen#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06875973
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07157774-1042@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Muvalaplin: Phase 3 readout est. (NCT07157774)
DESCRIPTION:Muvalaplin\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: Assessing the Impact of Muvalaplin on Major Cardiovascular Events 
 in Adults With Elevated Lipoprotein(a)\nEstimated primary completion: Marc
 h 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/muvalaplin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071577
 74
URL:https://assetmemo.bio/drug/muvalaplin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06930885-1199@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Lodoco (Colchicine (cardiovascular)): Phase 3 readout est. (NCT0693
 0885)
DESCRIPTION:Lodoco (Colchicine (cardiovascular))\, phase 3\, Atheroscleroti
 c Cardiovascular Disease.\nStudy: Polypill and Colchicine for Risk Reducti
 on in Atherosclerotic Cardiovascular Disease\nEstimated primary completion
 : May 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/colchicin
 e-cardiovascular#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06930885
URL:https://assetmemo.bio/drug/colchicine-cardiovascular#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551492-185@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20310524
DTEND;VALUE=DATE:20310525
SUMMARY:ribupatide: Phase 3 readout est. (NCT07551492)
DESCRIPTION:ribupatide\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 I
 n Participants With Atherosclerotic Cardiovascular Disease\nEstimated prim
 ary completion: 24 May 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ribupatide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07551492
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232069-1199@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Lodoco (Colchicine (cardiovascular)): Phase 3 readout est. (NCT0723
 2069)
DESCRIPTION:Lodoco (Colchicine (cardiovascular))\, phase 3\, Atheroscleroti
 c Cardiovascular Disease.\nStudy: PRE-EMPT: Prospective RandomizEd Evaluat
 ion and Management of Premature aTherosclerosis\nEstimated primary complet
 ion: July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/colch
 icine-cardiovascular#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07232069
URL:https://assetmemo.bio/drug/colchicine-cardiovascular#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232069-5401@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Rosuvastatin: Phase 3 readout est. (NCT07232069)
DESCRIPTION:Rosuvastatin\, phase 3\, Atherosclerotic Cardiovascular Disease
 .\nStudy: PRE-EMPT: Prospective RandomizEd Evaluation and Management of Pr
 emature aTherosclerosis\nEstimated primary completion: July 2031. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/rosuvastatin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07232069
URL:https://assetmemo.bio/drug/rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775339-1049@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Lerochol (Lerodalcibep): Phase 3 readout est. (NCT07775339)
DESCRIPTION:Lerochol (Lerodalcibep)\, phase 3\, Atherosclerotic Cardiovascu
 lar Disease.\nStudy: Long-Term Efficacy and Safety of Lerodalcibep in Chil
 dren and Adolescents With Familial Hypercholesterolemia\nEstimated primary
  completion: 31 July 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lerodalcibep#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07775339
URL:https://assetmemo.bio/drug/lerodalcibep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241390-117@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07241390)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Atherosclerotic Cardiovascu
 lar Disease.\nStudy: A Study of Orforglipron (LY3502970) on Cardiovascular
  Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chr
 onic Kidney Disease (ATTAIN-Outcomes)\nEstimated primary completion: Augus
 t 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0724
 1390
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136012-1039@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20311020
DTEND;VALUE=DATE:20311021
SUMMARY:Olpasiran: Phase 3 readout est. (NCT07136012)
DESCRIPTION:Olpasiran\, phase 3\, Atherosclerotic Cardiovascular Disease.\n
 Study: OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And L
 ipoprotein(a) Reduction to Prevent First Major Cardiovascular Events\nEsti
 mated primary completion: 20 October 2031. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/olpasiran#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07136012
URL:https://assetmemo.bio/drug/olpasiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05682378-1034@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20320325
DTEND;VALUE=DATE:20320326
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT05682378)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Long-term Safety and Tolerability of Inclisiran in Partic
 ipants With HeFH or HoFH Who Have Completed the Pediatric ORION-16\, ORION
 -13\, ORION-20\, or ORION-19 Studies\nEstimated primary completion: 25 Mar
 ch 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/inclisiran#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05682
 378
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06494501-1034@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06494501)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: The Prevent Coronary Artery Disease Trial\nEstimated prim
 ary completion: 30 June 2032. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/inclisiran#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06494501
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07058077-1048@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20331204
DTEND;VALUE=DATE:20331205
SUMMARY:Lipfendra (Enlicitide): Phase 2/3 readout est. (NCT07058077)
DESCRIPTION:Lipfendra (Enlicitide)\, phase 2/3\, Atherosclerotic Cardiovasc
 ular Disease.\nStudy: A Study of Enlicitide Decanoate (MK-0616\, an Oral P
 CSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hyp
 ercholesterolemia (MK-0616-029)\nEstimated primary completion: 4 December 
 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/enlicitide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07058077
URL:https://assetmemo.bio/drug/enlicitide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
